- Home
- ZEPP vs IPHA Comparison
ZEPP vs IPHA Comparison
Compare ZEPP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- IPHA
- Stock Information
- Founded
- ZEPP 2013
- IPHA 1999
- Country
- ZEPP Netherlands
- IPHA France
- Employees
- ZEPP N/A
- IPHA N/A
- Industry
- ZEPP Computer Manufacturing
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- IPHA Health Care
- Exchange
- ZEPP Nasdaq
- IPHA Nasdaq
- Market Cap
- ZEPP 148.3M
- IPHA 160.1M
- IPO Year
- ZEPP N/A
- IPHA 2019
- Fundamental
- Price
- ZEPP $11.13
- IPHA $2.03
- Analyst Decision
- ZEPP
- IPHA Strong Buy
- Analyst Count
- ZEPP 0
- IPHA 1
- Target Price
- ZEPP N/A
- IPHA $11.00
- AVG Volume (30 Days)
- ZEPP 1.4M
- IPHA 6.5K
- Earning Date
- ZEPP 08-03-2025
- IPHA 09-11-2025
- Dividend Yield
- ZEPP N/A
- IPHA N/A
- EPS Growth
- ZEPP N/A
- IPHA N/A
- EPS
- ZEPP N/A
- IPHA N/A
- Revenue
- ZEPP $181,183,000.00
- IPHA $20,831,349.00
- Revenue This Year
- ZEPP $758.69
- IPHA $209.83
- Revenue Next Year
- ZEPP N/A
- IPHA $83.15
- P/E Ratio
- ZEPP N/A
- IPHA N/A
- Revenue Growth
- ZEPP N/A
- IPHA N/A
- 52 Week Low
- ZEPP $2.06
- IPHA $1.29
- 52 Week High
- ZEPP $15.85
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ZEPP 64.77
- IPHA 61.03
- Support Level
- ZEPP $10.42
- IPHA $1.71
- Resistance Level
- ZEPP $15.85
- IPHA $2.10
- Average True Range (ATR)
- ZEPP 2.13
- IPHA 0.07
- MACD
- ZEPP 0.10
- IPHA 0.04
- Stochastic Oscillator
- ZEPP 60.20
- IPHA 82.50
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.